Journal article
Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus
European heart journal. Cardiovascular pharmacotherapy, v 11(8), pp 698-711
01 Dec 2025
PMID: 41143728
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Type 2 diabetes mellitus typically has the lipid features of elevated trigycerides, reduced HDL-cholesterol (both parts of the metabolic syndrome) and average or slightly elevated LDL-cholesterol. In consequence of hypertriglyceridemia, LDL particles are small and dense and therefore highly atherogenic. Outcome studies reveal that LDL-C lowering drugs have an above-average efficacy in type 2 diabetes as compared with non-diabetic patients. A minor increase of glycaemia in statin trials does not impair the beneficial cardiovascular results. Non-statin lipid lowering drugs do not impair glycaemia. Type 2 diabetes mellitus is now considered a major indication for lipid lowering drugs, thus there is a high value of and no major limitation for those compounds. Graphical AbstractCentral illustration: the central illustration depicts the major site of action as well as the level of evidence for cardiovascular risk reduction.
Metrics
1 Record Views
Details
- Title
- Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus
- Creators
- Heinz Drexel - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Festa - Vorarlberg Institute for Vascular Investigation and TreatmentThomas A Schmidt - University of CopenhagenBianca Rocca - LUM Jean Monnet UniversityDobromir Dobrev - Baylor College of MedicineStefan Agewall - Karolinska InstitutetJuan Tamargo - Hospital General Universitario Gregorio MarañónSusanne Kaser - Innsbruck Medical University
- Publication Details
- European heart journal. Cardiovascular pharmacotherapy, v 11(8), pp 698-711
- Publisher
- Oxford University Press
- Number of pages
- 14
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:001600526800001
- Scopus ID
- 2-s2.0-105025039725
- Other Identifier
- 991022197335204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Pharmacology & Pharmacy